Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies
NCT05920889 on ClinicalTrials.gov · last registry update 2025-03-07
Finished 25 October 2024, after enrolling 140 people. Primary outcome, as filed: Change of Modified Rankin Score. semaglutide is already approved in the US for cardiovascular disease, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P2
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Chinese University of Hong Kong
- Sponsor type
- Other
- Enrollment
- 140
- Started
- 2023-08-01
- Primary completion
- 2024-10-25 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change of Modified Rankin Score
Conditions studied
Stroke · Stroke, Acute · Stroke, Ischemic · Brain Diseases
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.